Log In
Friday 28th October 2016

Outrage at bonus

7th November 2006

01072006_Vaccination1.jpgThe boss of a US research company in charge of trials which almost killed six men has been awarded a $1.7m bonus.

Lawyers for some of the men on the doomed TGN1412 trial have hit out at the cash and share bonus package awarded to Parexel chief executive Josef von Rickenbach given eight months on from the trial which may have left the men at risk of developing cancer and auto-immune diseases.

The previously healthy men had volunteered to test the medication, designed to treat rheumatoid arthritis, leukaemia and multiple sclerosis. But shortly after being injected with it their heads and bodies rapidly swelled up. One had all his toes and parts of his fingers amputated.

A report by the Medicines and Healthcare products Regulatory Agency, the Government's drug watchdog, said Parexel had failed to follow several procedures.

The trials were carried out the company’s laboratory at Northwick Park Hospital on behalf of TeGenero, a German pharmaceutical company.

Accounts released by Parexel, show Mr von Rickenbach - who founded the clinical research organisation and is also its chairman – received around $1.76m dollars (£920,000) in cash and share options on top of a basic salary of $465,750.

Lawyers representing the men said they had received £10,000 each so far.

Parexel did not wish to comment.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016